This is a free preview for the upcoming Alector Inc IPO.
Company: Alector, Inc.
Symbol: ALEC
Description: They are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration.
Shares: 9.25 million
Price Range: $18.00-$20.00
Trade Date: 2/7
Underwriter(s): Morgan Stanley, BofA Merrill Lynch, Cowen, Barclays
Terms Added: 1-29-19
Business: Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. They are developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. Supporting their scientific approach, their Discovery Platform enables them to advance a broad portfolio of product candidates, validated by human genetics, which they believe will improve the probability of technical success over shorter development timelines.
The following table highlights their preclinical and clinical programs.
IPO Boutiuqe Color, Commentary & Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.